Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19F MRI of Perfluorinated Gases in Lung Transplant Recipients
NCT02019251Phase 1Completed
- Sponsor
- Hal C Charles
- Start
- Dec 2013
- Primary completion
- Jun 2014
- Modality
- GAS (Genetic analysis systems)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren in Chronic lung allograft rejection (CLAD), sponsored by Hal C Charles. Primary endpoint: Regional non-invasive images of pulmonary function at 1 day. Started Dec 2013; status: completed.
02
Drugs
perflutren
03
Conditions
Chronic lung allograft rejection (CLAD)
Beyond the preview
Go deeper on NCT02019251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019251.